These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32105673)

  • 1. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
    Liu X; Ding C; Tan W; Zhang A
    Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling pathway and molecular subgroups of medulloblastoma.
    Li KK; Lau KM; Ng HK
    Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Approaches in Targeted Therapy for Medulloblastoma in Children.
    Maier H; Dalianis T; Kostopoulou ON
    Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rationale for targeted therapies in medulloblastoma.
    MacDonald TJ; Aguilera D; Castellino RC
    Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
    Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medulloblastoma genomics in the modern molecular era.
    Kumar R; Liu APY; Northcott PA
    Brain Pathol; 2020 May; 30(3):679-690. PubMed ID: 31799776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Classification of Medulloblastoma.
    Kijima N; Kanemura Y
    Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic insights into medulloblastoma relapse.
    Peterson K; Turos-Cabal M; Salvador AD; Palomo-Caturla I; Howell AJ; Vieira ME; Greiner SM; Barnoud T; Rodriguez-Blanco J
    Pharmacol Ther; 2024 Aug; 260():108673. PubMed ID: 38857789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets.
    Bahmad HF; Poppiti RJ
    J Clin Pathol; 2020 May; 73(5):243-249. PubMed ID: 32034059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMI1 is a therapeutic target in recurrent medulloblastoma.
    Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
    Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
    Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
    Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma.
    Andrade AF; Borges KS; Suazo VK; Geron L; Corrêa CA; Castro-Gamero AM; de Vasconcelos EJ; de Oliveira RS; Neder L; Yunes JA; Dos Santos Aguiar S; Scrideli CA; Tone LG
    Invest New Drugs; 2017 Feb; 35(1):26-36. PubMed ID: 27785591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma.
    Zhu L; Yang Y; Li H; Xu L; You H; Liu Y; Liu Z; Liu X; Zheng D; Bie J; Li J; Song C; Yang B; Luo J; Chang Q
    Cancer Lett; 2022 Jun; 535():215630. PubMed ID: 35304257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.